Loading company…
SIRS Therapeutics develops FX06, a peptide derived from human fibrin, for patients with ARDS, SIRS and COVID-19, based in Munich.
Founded in 2020 and based in Munich, Germany, SIRS Therapeutics UG develops and provides FX06, a 28 amino acid peptide from human fibrin. The peptide reduces leukocyte extravasation and preserves the endothelial barrier. The company focuses on treating patients with Respiratory Distress Syndrome (ARDS), Systemic Inflammatory Response Syndrome (SIRS) and COVID-19.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in